Biotech startups that raised Series B in Massachusetts, United States
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Superluminal Medicines | Boston | Series B | $65.5M | 2026-09-03 |
| Simnova | Cambridge | Series B | $59.3M | 2026-08-18 |
| Elemental Machines | Cambridge | Series B | $5.7M | 2026-05-27 |
| Kytopen | Cambridge | Series B | $1.6M | 2026-04-07 |
| Atavistik Bio | Cambridge | Series B | $40.0M | 2026-03-05 |
| Precede Biosciences | Boston | Series B | $63.5M | 2026-01-12 |
| Diagonal Therapeutics | Watertown | Series B | $125.0M | 2026-01-08 |
| Nocion Therapeutics | Cambridge | Series B | $23.0M | 2026-01-07 |
8 rows of the CSV in 5 of its 18 columns.
- The 168 biotech startups in Massachusetts, United States whose last round is Series B have raised $17.5B in total.
- 24 of them closed their most recent round in the last 12 months, $1.6B combined.
- The largest of those rounds is Matchpoint Therapeutics' $150.0M Series B, dated October 2026.
- The most recent is Rgenta Therapeutics' $41.9M Series B on 3 November 2026.
- RA Capital Management is an investor in 4 of them, more than any other fund.
- Health care is the most common other sector, with 157 companies (93%).
- 20% were founded in 2020 or later; the median founding year is 2016.
- The most common team size is 11 to 50 employees (52% of companies with a recorded size).
- 1 is a unicorn, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
26 of 168| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Superluminal Medicines | Superluminal Medicines develops small-molecule therapeutics by combining AI, biology, and chemistry. | Artificial intelligence | Boston | Series B | $65.5M | 2026-09-03 | $223.5M | Insight Partners, RA Capital Management, NVentures | 11 to 50 | 2022 |
| Simnova | Simnova Biotherapeutics develops CAR-based cell therapies for treating cancer. | Biotech | Cambridge | Series B | $59.3M | 2026-08-18 | $87.2M | Oriza Seed Capital (Oriza Yuandian), Youshan Capital, PagodaTree Partners +1 | 51 to 100 | 2019 |
| Elemental Machines | Elemental Machines provides data-driven insights to improve research, laboratory operations, and manufacturing outcomes. | Artificial intelligence | Cambridge | Series B | $5.7M | 2026-05-27 | $66.5M | Founders Fund, Tau Ventures, Rock Health Capital +2 | 11 to 50 | 2015 |
| Kytopen | Kytopen develops genome engineering platforms for cell therapy research and manufacturing. | Biotech | Cambridge | Series B | $1.6M | 2026-04-07 | $39.1M | National Science Foundation, MassVentures, Alexandria Venture Investments +1 | 11 to 50 | 2017 |
| Atavistik Bio | Atavistik Bio develops precision allosteric small molecules to treat metabolic diseases and cancer. | Biotech | Cambridge | Series B | $40.0M | 2026-03-05 | $260.0M | Lux Capital, The Column Group, Nextech Invest | 11 to 50 | 2021 |
| Precede Biosciences | Precede Biosciences develops blood-based tests that reveal disease-defining transcriptional biology. | Biotech | Boston | Series B | $63.5M | 2026-01-12 | $140.5M | Bristol-Myers Squibb, Lilly Asia Ventures, 5AM Ventures +2 | 11 to 50 | 2005 |
| Diagonal Therapeutics | Diagonal Therapeutics develops targeted therapies for cancer and genetic diseases. | Biotech | Watertown | Series B | $125.0M | 2026-01-08 | $253.0M | Lightspeed Venture Partners, RA Capital Management, Atlas Venture +1 | 11 to 50 | 2022 |
| Nocion Therapeutics | Nocion Therapeutics develops pharmaceuticals to treat conditions arising from neurogenic inflammation. | Biotech | Cambridge | Series B | $23.0M | 2026-01-07 | $134.0M | Canaan Partners, F-Prime, OUP (Osage University Partners) +2 | 11 to 50 | 2017 |
| Myrtelle | Myrtelle is a gene therapy company that runs clinical trials for rare monogenetic disorders. | Biotech | Wakefield | Series B | $30.5M | 2025-12-23 | $57.6M | Panacea Venture | 11 to 50 | 2020 |
| Manifold | Manifold provides machine learning tools that analyze operational data to support industrial and energy decisions. | Artificial intelligence | Newton | Series B | $18.0M | 2025-12-18 | $40.5M | TQ Ventures, Calibrate Ventures, SK Ventures +1 | 101 to 250 | 2016 |
| Sanegene Bio | Sanegene Bio develops an RNAi drug discovery platform aimed at unmet clinical needs. | Biotech | Woburn | Series B | $110.0M | 2025-12-08 | $240.0M | Shenzhen Capital Group, Qiming Venture Partners, Northern Light Venture Capital +1 | 51 to 100 | 2021 |
| Kailera Therapeutics | Kailera Therapeutics develops injectable and oral therapies for chronic weight management. | Biotech | Waltham | Series B | $600.0M | 2025-10-14 | $1.0B | Atlas Venture, Bain Capital Life Sciences, RTW Investments | 101 to 250 | 2024 |
| AIRNA | AIRNA develops RNA editing technologies to create medicines for various diseases. | Biotech | Cambridge | Series B | $155.0M | 2025-04-01 | $245.0M | ARCH Venture Partners, Alexandria Venture Investments, Forbion Capital Partners +2 | 51 to 100 | 2021 |
| Stellaromics | Stellaromics develops 3D in situ multi-omic analysis technology for biotechnology research. | Biotech | Natick | Series B | $80.0M | 2025-02-11 | $105.0M | Plaisance Capital Management | 11 to 50 | 2022 |
| VideaHealth | VideaHealth offers dentistAI software that automatically detects pathologies in dental imaging to help dentists avoid missed diagnoses. | Biotech | Boston | Series B | $40.0M | 2025-01-28 | $66.5M | Spark Capital, Zetta Venture Partners, Pillar VC +2 | 51 to 100 | 2018 |
| Seismic Therapeutic | Seismic Therapeutic applies machine learning to develop drugs for immunology. | Biotech | Watertown | Series B | $25.0M | 2024-09-12 | $247.0M | Lightspeed Venture Partners, Gaingels, Bessemer Venture Partners +2 | 51 to 100 | 2020 |
| Cardurion Pharmaceuticals | Cardurion Pharmaceuticals develops cardiovascular therapeutics for heart failure and related diseases. | Biotech | Boston | Series B | $260.0M | 2024-07-16 | $603.1M | New Enterprise Associates, Google Ventures, Fidelity +1 | 11 to 50 | 2017 |
| Qlaris Bio | Qlaris Bio develops first-in-class therapies for serious and debilitating eye diseases. | Biotech | Wellesley | Series B | $24.0M | 2024-04-22 | $49.0M | Correlation Ventures, Canaan Partners, New Leaf Venture Partners +1 | 1 to 10 | 2019 |
| NextPoint Therapeutics | NextPoint Therapeutics develops therapeutics to treat cancer patients as a clinical-stage biotechnology company. | Biotech | Cambridge | Series B | $42.5M | 2024-02-14 | $122.5M | Invus, Leaps by Bayer, Catalio Capital Management +2 | 51 to 100 | 2020 |
| Comanche Biopharma | Comanche Biopharma works to make pregnancies around the world safer. | Biotech | Concord | Series B | $75.0M | 2024-01-17 | $111.1M | New Enterprise Associates, Google Ventures, F-Prime +2 | 11 to 50 | 2020 |
| ROME Therapeutics | ROME Therapeutics develops therapies for cancer and autoimmune diseases by targeting the repeatome. | Biotech | Cambridge | Series B | $72.0M | 2023-09-12 | $199.0M | Andreessen Horowitz, Google Ventures, Alexandria Venture Investments +2 | 11 to 50 | 2020 |
| Mariana Oncology | Mariana Oncology conducts biotechnology research in the oncology field. | Biotech | Watertown | Series B | $175.0M | 2023-09-07 | $250.0M | RA Capital Management, Forbion Capital Partners, Surveyor Capital +1 | 11 to 50 | 2021 |
| Asimov | Asimov uses artificial intelligence to build tools for designing and manufacturing therapeutics. | Artificial intelligence | Boston | Series B | $175.0M | 2023-01-05 | $205.0M | Andreessen Horowitz, DCVC, Fidelity +2 | 101 to 250 | 2017 |
| InsideTracker | InsideTracker provides a platform that analyzes and tracks key biochemical and physiological markers. | Biotech | Cambridge | Series B | $15.0M | 2022-09-06 | $18.2M | OurCrowd, MassVentures, Puget Sound Venture Club +2 | 11 to 50 | 2009 |
| BostonGene Unicorn | BostonGene provides biomedical software for analyzing patients and personalizing cancer therapy. | Biotech | Waltham | Series B | $150.0M | 2022-04-06 | $200.0M | Japan Industrial Partners | 251 to 500 | 2015 |
| Phylos | Phylos discovers and develops novel biopharmaceutical products. | Biotech | Lexington | Series B | $25.0M | 2001-01-01 | Sprout Group, Three Arch Partners, Lone Pine Capital |
Table 1. Biotech startups that raised Series B in Massachusetts, United States: the 26 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 168.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Diagonal Therapeutics | Diagonal Therapeutics develops targeted therapies for cancer and genetic diseases. | Biotech | Watertown | Series B | $125.0M | 2026-01-08 | $253.0M | Lightspeed Venture Partners, RA Capital Management, Atlas Venture +1 | 11 to 50 | 2022 |
| 2 | Sanegene Bio | Sanegene Bio develops an RNAi drug discovery platform aimed at unmet clinical needs. | Biotech | Woburn | Series B | $110.0M | 2025-12-08 | $240.0M | Shenzhen Capital Group, Qiming Venture Partners, Northern Light Venture Capital +1 | 51 to 100 | 2021 |
| 3 | Superluminal Medicines | Superluminal Medicines develops small-molecule therapeutics by combining AI, biology, and chemistry. | Artificial intelligence | Boston | Series B | $65.5M | 2026-09-03 | $223.5M | Insight Partners, RA Capital Management, NVentures | 11 to 50 | 2022 |
| 4 | Precede Biosciences | Precede Biosciences develops blood-based tests that reveal disease-defining transcriptional biology. | Biotech | Boston | Series B | $63.5M | 2026-01-12 | $140.5M | Bristol-Myers Squibb, Lilly Asia Ventures, 5AM Ventures +2 | 11 to 50 | 2005 |
| 5 | Simnova | Simnova Biotherapeutics develops CAR-based cell therapies for treating cancer. | Biotech | Cambridge | Series B | $59.3M | 2026-08-18 | $87.2M | Oriza Seed Capital (Oriza Yuandian), Youshan Capital, PagodaTree Partners +1 | 51 to 100 | 2019 |
| 6 | Atavistik Bio | Atavistik Bio develops precision allosteric small molecules to treat metabolic diseases and cancer. | Biotech | Cambridge | Series B | $40.0M | 2026-03-05 | $260.0M | Lux Capital, The Column Group, Nextech Invest | 11 to 50 | 2021 |
| 7 | Myrtelle | Myrtelle is a gene therapy company that runs clinical trials for rare monogenetic disorders. | Biotech | Wakefield | Series B | $30.5M | 2025-12-23 | $57.6M | Panacea Venture | 11 to 50 | 2020 |
| 8 | Nocion Therapeutics | Nocion Therapeutics develops pharmaceuticals to treat conditions arising from neurogenic inflammation. | Biotech | Cambridge | Series B | $23.0M | 2026-01-07 | $134.0M | Canaan Partners, F-Prime, OUP (Osage University Partners) +2 | 11 to 50 | 2017 |
| 9 | Manifold | Manifold provides machine learning tools that analyze operational data to support industrial and energy decisions. | Artificial intelligence | Newton | Series B | $18.0M | 2025-12-18 | $40.5M | TQ Ventures, Calibrate Ventures, SK Ventures +1 | 101 to 250 | 2016 |
| 10 | Elemental Machines | Elemental Machines provides data-driven insights to improve research, laboratory operations, and manufacturing outcomes. | Artificial intelligence | Cambridge | Series B | $5.7M | 2026-05-27 | $66.5M | Founders Fund, Tau Ventures, Rock Health Capital +2 | 11 to 50 | 2015 |
Table 2. Biotech startups that raised Series B in Massachusetts, United States: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | RA Capital Management | Startup incubator | Boston, United States | 4 | 2% | 2 | Superluminal Medicines, Diagonal Therapeutics |
| 2 | Google Ventures | Corporate venture arm | San Francisco, United States | 4 | 2% | ||
| 3 | Alexandria Venture Investments | Venture capital firm | Pasadena, United States | 3 | 2% | 1 | Kytopen |
| 4 | Atlas Venture | Venture capital firm | Cambridge, United States | 3 | 2% | 1 | Diagonal Therapeutics |
| 5 | F-Prime | Venture capital firm | Cambridge, United States | 3 | 2% | 1 | Nocion Therapeutics |
| 6 | Andreessen Horowitz | Venture capital firm | Menlo Park, United States | 3 | 2% | ||
| 7 | New Enterprise Associates | Venture capital firm | Menlo Park, United States | 3 | 2% | ||
| 8 | Insight Partners | Private equity firm | New York, United States | 2 | 1% | 1 | Superluminal Medicines |
| 9 | Digitalis Ventures | Venture capital firm | New York, United States | 2 | 1% | 1 | Elemental Machines |
| 10 | KdT Ventures | Venture capital firm | Austin, United States | 2 | 1% | 1 | Elemental Machines |
| 11 | MassVentures | Venture capital firm | Boston, United States | 2 | 1% | 1 | Kytopen |
| 12 | National Science Foundation | Entrepreneurship program | Alexandria, United States | 2 | 1% | 1 | Kytopen |
| 13 | Lilly Asia Ventures | Venture capital firm | Shanghai, China | 2 | 1% | 1 | Precede Biosciences |
| 14 | Bristol-Myers Squibb | Venture capital firm | New York, United States | 2 | 1% | 1 | Precede Biosciences |
| 15 | Lightspeed Venture Partners | Venture capital firm | Menlo Park, United States | 2 | 1% | 1 | Diagonal Therapeutics |
Table 3. Biotech startups that raised Series B in Massachusetts, United States: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 157 | 93% | $16.7B |
| Software | 17 | 10% | $1.5B |
| Artificial intelligence | 9 | 5% | $956.7M |
| Hardware | 5 | 3% | $194.0M |
| Commerce | 1 | 1% | $55.0M |
Table 4. Biotech startups that raised Series B in Massachusetts, United States by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series B | 168 | 100% | $41.3M |
Table 5. Biotech startups that raised Series B in Massachusetts, United States by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 6. Biotech startups that raised Series B in Massachusetts, United States by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 1 | 4% | $41.9M |
| October 2026 | 2 | 8% | $285.0M |
| September 2026 | 1 | 4% | $65.5M |
| August 2026 | 1 | 4% | $59.3M |
| June 2026 | 3 | 12% | $168.8M |
| May 2026 | 2 | 8% | $127.7M |
| April 2026 | 1 | 4% | $1.6M |
| March 2026 | 2 | 8% | $117.0M |
| January 2026 | 6 | 25% | $385.5M |
| December 2025 | 4 | 17% | $278.5M |
| November 2025 | 1 | 4% | $59.2M |
Table 7. Biotech startups that raised Series B in Massachusetts, United States: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 19 | 11% | $1.3B |
| 2025 | 19 | 11% | $1.8B |
| 2024 | 14 | 8% | $972.0M |
| 2023 | 20 | 12% | $1.8B |
| 2022 | 15 | 9% | $1.3B |
| 2021 | 15 | 9% | $1.2B |
Table 8. Biotech startups that raised Series B in Massachusetts, United States by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 4 | 2% |
| 2020 to 2022 | 30 | 18% |
| 2015 to 2019 | 61 | 37% |
| 2010 to 2014 | 28 | 17% |
| Before 2010 | 44 | 26% |
Table 9. Biotech startups that raised Series B in Massachusetts, United States by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 24 | 15% |
| 11 to 50 | 85 | 52% |
| 51 to 100 | 38 | 23% |
| 101 to 250 | 12 | 7% |
| 251 to 500 | 3 | 2% |
| 501 to 1,000 | 1 | 1% |
| 10,001 or more | 1 | 1% |
Table 10. Biotech startups that raised Series B in Massachusetts, United States by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series B and its headquarters is in Massachusetts, United States. On 16 November 2026 that is 168 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 26 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 168 rows: 10 have no round amount, 0 no city and 16 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Massachusetts, United States whose last round is Series B are on the list?
- 168, in the file dated 16 November 2026. 24 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 168 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.